Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bloch

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Journal of the International AIDS Society|November 14, 2014
Effectiveness of a team intervention in reducing modifiable cardiovascular disease risk in HIV-infected subjects on antiretroviral therapyMark Bloch, Avindra Jayewardene, Trina Vincent, et al.
AIDS (London, England)|January 3, 2020
Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeksMirella Carr, Robyn Richardson, Winnie Tong, et al.
Pain Management|January 30, 2018
Meaningful relief with flurbiprofen 8.75 mg spray in patients with sore throat due to upper respiratory tract infectionFerdinandus de Looze, Marc Russo, Mark Bloch, et al.
AIDS (London, England)|February 9, 2002
The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapyGilbert R Kaufmann, Mark Bloch, Robert Finlayson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2013
Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adultsFrederick J Lee, Janaki Amin, Mark Bloch, et al.
Journal of the Neurological Sciences|August 2, 2024
Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot studyLilian Chow, Julia Presanis, Nikki McIntyre, et al.
Journal of Clinical and Experimental Neuropsychology|January 6, 2017
Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedureJody Kamminga, Mark Bloch, Trina Vincent, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 22, 2009
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trialAllison Martin, Mark Bloch, Janaki Amin, et al.
The European Journal of General Practice|March 31, 2016
Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trialFerdinandus de Looze, Marc Russo, Mark Bloch, et al.
Journal of Neurovirology|December 12, 2022
Low incidence of advanced neurological burden but high incidence of age-related conditions that are dementia risk factors in aging people living with HIV: a data-linkage 10-year follow-up studyHtein Linn Aung, Mark Bloch, Trina Vincent, et al.
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Journal of the International AIDS Society|November 14, 2014
Effectiveness of a team intervention in reducing modifiable cardiovascular disease risk in HIV-infected subjects on antiretroviral therapyMark Bloch, Avindra Jayewardene, Trina Vincent, et al.
AIDS (London, England)|January 3, 2020
Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeksMirella Carr, Robyn Richardson, Winnie Tong, et al.
Pain Management|January 30, 2018
Meaningful relief with flurbiprofen 8.75 mg spray in patients with sore throat due to upper respiratory tract infectionFerdinandus de Looze, Marc Russo, Mark Bloch, et al.
AIDS (London, England)|February 9, 2002
The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapyGilbert R Kaufmann, Mark Bloch, Robert Finlayson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2013
Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adultsFrederick J Lee, Janaki Amin, Mark Bloch, et al.
Journal of the Neurological Sciences|August 2, 2024
Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot studyLilian Chow, Julia Presanis, Nikki McIntyre, et al.
Journal of Clinical and Experimental Neuropsychology|January 6, 2017
Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedureJody Kamminga, Mark Bloch, Trina Vincent, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 22, 2009
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trialAllison Martin, Mark Bloch, Janaki Amin, et al.
The European Journal of General Practice|March 31, 2016
Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trialFerdinandus de Looze, Marc Russo, Mark Bloch, et al.
Journal of Neurovirology|December 12, 2022
Low incidence of advanced neurological burden but high incidence of age-related conditions that are dementia risk factors in aging people living with HIV: a data-linkage 10-year follow-up studyHtein Linn Aung, Mark Bloch, Trina Vincent, et al.
Pageof 9